Karyopharm Therapeutics (KPTI) Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in PFS in Patients with Multiple Myeloma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Karyopharm Therapeutics (KPTI) Prices 6.25M Share Common Offering at $24/Sh
March 4, 2020 5:54 AM ESTKaryopharm Therapeutics Inc. (NASDAQ: KPTI) today announced the pricing of its previously announced registered underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $24.00 per share. The gross proceeds to Karyopharm from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $150.0 million. The offering is... More
Karyopharm Therapeutics (KPTI) Announces Proposed $150M Public Offering of Common Stock
March 2, 2020 4:17 PM ESTKaryopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock. In addition, Karyopharm also intends to grant the underwriters a 30-day option to purchase up to... More
Karyopharm Therapeutics (KPTI) PT Raised to $35 at Baird
March 2, 2020 8:29 AM ESTBaird analyst Michael Ulz raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $35.00 (from $25.00) while maintaining an Outperform rating following better-than-expected BOSTON study data.
The analyst commented, "This morning, Karyopharm announced highly anticipated Phase 3 results from the BOSTON study of... More
